Apricus Biosciences (NASDAQ: APRI) is focused on advancing the development and commercialization of its innovative, life-improving treatment products in urology and rheumatology. The company’s pipeline includes Vitaros®, a locally applied topical cream for the treatment of erectile dysfunction, a condition affecting roughly 150 million men worldwide. Containing alprostadil in combination with the company’s novel excipient, Vitaros delivers a rapid onset with significant efficacy and an encouraging safety profile. In a study of more than 3,000 patients, Vitaros demonstrated positive, clinically meaningful responses in measures of erectile function. The FDA recently determined that Vitaros, under current regulations, is now considered a drug-device combination. Apricus intends to re-submit the Vitaros New Drug Application as soon as possible in 2017. The product is already approved in Canada and certain countries in Europe, Latin America and the Middle East, and it is being commercialized in several countries in Europe.
To learn more, visit www.apricusbio.com
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (NASDAQ: APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Canada and certain countries in Europe, Latin America and the Middle East and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Recordati Ireland Ltd. (Recordati), Ferring International Center S.A. (Ferring Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
